EGFR and non-small cell lung carcinoma: Consequently, it remains unclear whether the EMT signatures derived from cell panels that included both EGFR-wild type and -mutant cell lines and validated in predominantly EGFR-wild type clinical cohorts are optimal for the study of EMT as a basis for acquired resistance to EGFR TKIs in EGFR-mutant NSCLC.